Feeley Kevin 4

What Happened
Kevin Feeley, Chief Financial Officer of GeneDx Holdings Corp. (WGS), acquired 1,986 shares of the company's Class A common stock on March 6, 2026. The shares were purchased at $88.11 per share (the closing price that day) for a total of $174,986. The transaction is reported as an acquisition/award (Code A) rather than a sale.

Key Details

• Transaction date: 2026-03-06; filing date: 2026-03-09 (appears timely, within the usual 2-business-day Form 4 window).
• Shares acquired: 1,986 at $88.11 per share. Total value: $174,986.
• Transaction type/code: A (award/grant/other acquisition).
• Footnote: The shares were acquired directly from the issuer under a Subscription Agreement and the transaction was exempt pursuant to Rule 16b-3(d).
• Shares owned after transaction: Not specified in the provided filing.

Context
This was a company-issued acquisition (purchase directly from the issuer), which is different from an open-market buy or the exercise of options. Purchases or awards by executives can be more informative than sales, but they do not by themselves explain intent—this filing documents the transfer and price only. The Rule 16b-3(d) reference indicates the transaction followed an exemption applicable to certain issuer-to-officer transfers.